+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNAi Therapeutics Market - Global Forecast 2026-2032- Product Image
RNAi Therapeutics Market - Global Forecast 2026-2032- Product Image
New

RNAi Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124468
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

RNAi therapeutics are progressing into a transformative phase, where success depends on delivery innovation, robust manufacturing, and strategic market access. Senior leaders in biopharma, manufacturing, and investment circles are closely monitoring this shift as RNAi technology demonstrates clinical validity and operational scalability.

Market Snapshot: RNAi Therapeutics Market Growth and Opportunity

The RNAi Therapeutics Market expanded substantially, growing from USD 5.54 billion in 2025 to USD 6.36 billion in 2026, and is projected to sustain a CAGR of 15.53%, ultimately reaching USD 15.23 billion by 2032. This trend highlights increasing confidence in RNAi applications, particularly as RNAi moves from breakthrough status to a routine part of drug pipeline strategies.

Scope & Segmentation: Understanding Market Layers and Regional Dynamics

  • Therapeutic Applications: Includes genetics-driven disorders, cardiometabolic and inflammatory conditions that benefit from precise gene silencing.
  • Molecule Types: Encompasses small interfering RNA (siRNA), ligand-conjugated formats, and lipid nanoparticle (LNP) enabled options.
  • Delivery Technologies: Addresses conjugation chemistry advancements, LNP improvements, and tailored formulation know-how for expanding into new tissue targets.
  • Administration Routes: Covers subcutaneous, intravenous, and alternative dosing strategies adapted for patient convenience and adherence.
  • Commercial Pathways: Incorporates specialty pharmacy, cold-chain management, clinician and patient services integral to product adoption.
  • Development Stages: Spans early research, clinical validation, late-stage scaling, and post-launch commercialization with tailored value drivers throughout the lifecycle.
  • Geographies: Examines Americas, Europe, Middle East and Africa (MEA), and Asia Pacific (APAC), capturing unique regulatory environments, reimbursement models, and supply chain requirements.

These segments shape competitive positioning, delivery requirements, and product differentiation as RNAi matures as a mainstream drug platform. Market relevance extends to product owners and solution providers seeking to align product design with care pathways and regional access strategies.

Key Takeaways for Decision Makers

  • Delivery platform breakthroughs and conjugation improvements are driving RNAi therapeutic expansion beyond liver indications and into larger chronic disease opportunities.
  • Integrated planning—combining target selection, delivery optimization, and manufacturing scalability—is crucial to converting clinical promise into reliable commercial performance.
  • Regulators and payers require robust evidence of durable benefit, adherence improvement, and measurable quality-of-life impact to support access and premium positioning.
  • Specialty channels, supply chain management, and coordinated clinician education influence uptake and persistence, demanding early investment in workflow solutions.
  • Lifecycle advantage now favors organizations with repeatable execution, cross-functional expertise, and platform modularity rather than isolated scientific wins.

Tariff Impact: Supply Chain Resilience Now Strategic

Recent United States tariff changes have heightened the need for resilient RNAi supply chains. Critical input categories including oligonucleotide building blocks, reagents, single-use process systems, and packaging face increased landed costs and procurement complexity. To manage these risks, RNAi developers are:

  • Dual-sourcing key materials to protect against supply fluctuations.
  • Negotiating long-term contracts that address cost pass-through and supply disruptions.
  • Regionalizing manufacturing and fill-finish operations to reduce cross-border risk and accelerate response time.

Companies that treat supply chain strategy as a core value driver can maintain production timelines and ensure reliable patient supply despite evolving policy environments.

Methodology & Data Sources

This report leverages a dual approach: structured secondary research from peer-reviewed sources, regulatory publications, and disclosed market activities, combined with primary validation through interviews with industry stakeholders. Triangulation reduces bias and ensures findings reflect current realities in RNAi science, operations, and access.

Why This Report Matters

  • Offers actionable insights enabling leaders to integrate delivery, manufacturing, and market access considerations early in development.
  • Equips decision makers to proactively strengthen supply chains, anticipate evidence requirements, and assess partnership options.
  • Helps stakeholders align resources with shifting therapeutic opportunities and regional adoption drivers.

Conclusion: Strategic Integration Defines the Future of RNAi

Market leadership in RNAi will be set by those who seamlessly combine delivery innovation with manufacturing readiness and evidence-driven access. Adaptability across supply, regulatory, and clinical dimensions is key to sustained growth as the therapeutic category matures.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. RNAi Therapeutics Market, by Delivery Technology
8.1. Exosomes
8.2. GalNAc Conjugates
8.3. Lipid Nanoparticles
8.4. Polymeric Nanoparticles
8.5. Viral Vectors
9. RNAi Therapeutics Market, by Therapeutic Molecule Type
9.1. Microrna
9.2. Short Hairpin Rna
9.3. Small Interfering Rna
10. RNAi Therapeutics Market, by Development Stage
10.1. Commercial
10.2. Phase I
10.3. Phase Ii
10.4. Phase Iii
10.5. Preclinical
11. RNAi Therapeutics Market, by Route Of Administration
11.1. Intranasal
11.2. Intravenous
11.3. Intravitreal
11.4. Subcutaneous
12. RNAi Therapeutics Market, by Formulation Type
12.1. Liquid Formulation
12.2. Lyophilized Formulation
13. RNAi Therapeutics Market, by Indication
13.1. Cardiovascular Disorders
13.2. Infectious Diseases
13.3. Metabolic Disorders
13.4. Oncology
13.4.1. Hematological Malignancies
13.4.1.1. Leukemia
13.4.1.2. Lymphoma
13.4.1.3. Myeloma
13.4.2. Solid Tumors
13.4.2.1. Breast Cancer
13.4.2.2. Liver Cancer
13.4.2.3. Lung Cancer
13.5. Rare Diseases
14. RNAi Therapeutics Market, by End User
14.1. Academic Institutions
14.2. Hospitals
14.3. Research Laboratories
14.4. Specialty Clinics
15. RNAi Therapeutics Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. RNAi Therapeutics Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. RNAi Therapeutics Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States RNAi Therapeutics Market
19. China RNAi Therapeutics Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. Alnylam Pharmaceuticals, Inc.
20.6. Arbutus Biopharma Corporation
20.7. Arbutus Biopharma Corporation
20.8. Arrowhead Pharmaceuticals, Inc.
20.9. Benitec Biopharma Limited
20.10. Dynacure SAS
20.11. Novartis AG
20.12. OliX Pharmaceuticals, Inc.
20.13. Ona Therapeutics SL
20.14. Phio Pharmaceuticals Corp.
20.15. Quark Pharmaceuticals, Inc.
20.16. Roche Holding AG
20.17. Silence Therapeutics plc
20.18. Simaomics, Inc.
List of Figures
FIGURE 1. GLOBAL RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 167. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 168. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 169. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 171. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 172. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 173. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 174. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 188. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 189. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 190. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 191. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 193. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 194. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 195. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 196. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 197. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 212. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 213. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 214. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 216. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 217. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 218. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 219. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 220. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. GCC RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 222. GCC RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 223. GCC RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 224. GCC RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 225. GCC RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. GCC RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 227. GCC RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 228. GCC RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 229. GCC RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 230. GCC RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 231. GCC RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. BRICS RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. BRICS RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 245. BRICS RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 246. BRICS RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 247. BRICS RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 248. BRICS RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 249. BRICS RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 250. BRICS RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 251. BRICS RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 252. BRICS RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 253. BRICS RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. G7 RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 255. G7 RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 256. G7 RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 257. G7 RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 258. G7 RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. G7 RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 260. G7 RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 261. G7 RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 262. G7 RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 263. G7 RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 264. G7 RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 265. NATO RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 266. NATO RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 267. NATO RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 268. NATO RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 269. NATO RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 270. NATO RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 271. NATO RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 272. NATO RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 273. NATO RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 274. NATO RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 275. NATO RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 288. CHINA RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 289. CHINA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 290. CHINA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 291. CHINA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 292. CHINA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 293. CHINA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 294. CHINA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 295. CHINA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 296. CHINA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 297. CHINA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 298. CHINA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this RNAi Therapeutics market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Benitec Biopharma Limited
  • Dynacure SAS
  • Novartis AG
  • OliX Pharmaceuticals, Inc.
  • Ona Therapeutics SL
  • Phio Pharmaceuticals Corp.
  • Quark Pharmaceuticals, Inc.
  • Roche Holding AG
  • Silence Therapeutics plc
  • Simaomics, Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.36 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.23 Billion
Compound Annual Growth Rate15.5%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2025-2033 - Product Image

Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
RNAi Therapeutics Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

RNAi Therapeutics Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 87 Pages
  • Global
From
Antisense & Rnai Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antisense & Rnai Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Antisense & RNAi Therapeutics Market Report 2025 - Product Image

Antisense & RNAi Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
RNAi Technology Market - Global Strategic Business Report - Product Image

RNAi Technology Market - Global Strategic Business Report

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.